Researchers present three studies highlighting advances in clinical cardiology, including a new drug-exercise combination that improves image quality and reduces side effects. The studies also explore the best medical and interventional treatment for patients with acute coronary syndromes.
A Phase 1 study evaluating a novel protein kinase C inhibitor, KAI-9803, suggests potential benefit in healing time and tissue function for heart attack patients. The trial showed improved tissue perfusion and reduced infarct size at lower dose levels.
A new study presents the first US controlled clinical trial using muscle stem cells to treat congestive heart failure. The procedure involves injecting autologous skeletal myoblasts into scarred tissue via a minimally invasive catheter, showing improved quality of life and potential cardiac function.
New implantable device stimulates body's regulatory systems to control high blood pressure; computerized angioplasty protocol reduces risk of renarrowing and complications after coronary stenting.
A Phase 1 trial of mesenchymal stem cells (MSCs) has shown significant improvements in heart function and reduced side effects in patients with acute myocardial infarction (MI). The study, led by Joshua Hare, M.D., found that MSC-treated patients had lower rates of cardiac arrhythmias and improved heart, lung, and global function.
Researchers studied the outcomes of treating ST- elevation myocardial infarction with PCI alone or with distal protection, finding similar major adverse cardiac events and electrocardiographic results. However, post-procedure blood flow was improved in patients treated with distal protection.
Researchers present new catheter-based approaches to repairing the mitral valve and treating coronary plaque, showing improved safety and feasibility. The MONARC system and sideKick stenting system demonstrate significant benefits in patients with moderate-to-severe mitral regurgitation and bifurcation lesions.
Researchers examined long-term follow-up of stents placed in infants with congenital heart disease, finding sustained benefits and the ability to safely enlarge stents as children grow. Additionally, studies investigated percutaneous pulmonary valve implantation, analyzing its mid-term outcomes and impact on device removal.
The SPIRIT-III trial shows that the Xience V Everolimus Eluting Coronary Stent System reduces target vessel failure, ischemic-driven revascularization procedures, and major adverse cardiac events compared to paclitaxel-eluting stents. This suggests a potential enhancement of outcomes for patients with coronary artery disease.
Researchers evaluated the safety and performance of a new bioabsorbable stent that eliminates several problems associated with metallic stents. At 30 days, device success was extremely high, and no patients experienced major adverse cardiac events or stent thrombosis.
A novel platelet therapy, SCH 530348, has demonstrated safety and efficacy in reducing percutaneous coronary intervention (PCI) complications. Major adverse events were reduced by 1.6-3.5% in low-dose cohorts compared to placebo. The treatment also showed a lower risk of death or major adverse events and heart attack compared to placebo.
Researchers investigate lifestyle choices and their impact on heart risks, exploring the effects of dark chocolate and nicotine patches on cardiovascular health. Studies find that flavonoids in dark chocolate can improve endothelial function in adults with BMI between 25-35 kg/m2.
A study comparing drug-eluting stents (DES) and bare-metal stents (BMS) found similar rates of complications, including stent thrombosis, MI, and mortality. However, DES patients had a slightly increased risk of stent thrombosis and heart attack between 12-15 months after implantation.
A new multislice CT scan can quickly detect fatty blockages in the heart's arteries, ruling out heart attacks and reducing diagnostic time. This simple outpatient scan allows doctors to confidently send home patients with normal coronary arteries, while accurately identifying those with serious heart disease.
The new guidelines emphasize the importance of treating both diabetes and cardiovascular diseases simultaneously. The guidelines recommend using stress testing and echocardiography to confirm a diagnosis of valvular heart disease, and emphasize the need for precise risk stratification before treatment decisions are made.
A study examines the relationship between plaque build-up and artery blockage in patients with moderate risk of coronary artery disease. The results show that MSCT detects atherosclerosis, while MPI identifies ischemia, suggesting that narrowing of coronary arteries may not harm blood flow to the heart.
A panel of national experts has developed a plan to improve the use of imaging technologies in patients with cardiovascular disease. The proposed action plan focuses on four key aspects: selecting the best imaging technique for each individual patient, acquiring high-quality images, correctly interpreting the results, and communicating...
Researchers developed a gene transfer method using the mutant form of apolipoprotein A-I (Apo A-I Milano) to treat vascular inflammation and plaque buildup. The study found that Apo A-I Milano gene transfer resulted in a 65% reduction in plaque buildup, compared to a 25% decrease with the normal HDL gene.
Preliminary research suggests that famotidine, a heartburn medication, can help decrease the effects of chronic heart failure by blocking a chemical reaction that damages diseased hearts. However, more testing is required to verify the results, including dosage and safety issues.
Researchers found that elevated troponin-T and N-terminal pro-B-type natriuretic peptide levels in the blood indicate high risk of deadly heart attacks. Patients with low levels may not benefit from aggressive treatment and could be harmed by invasive procedures.
The new ACC/AHA/ESC Guidelines outline recommendations for the evaluation and treatment of patients with ventricular arrhythmias and sudden cardiac death, addressing inconsistencies in previous guidelines. The guidelines provide individualized management based on symptom burden and severity of underlying heart disease.
The American College of Cardiology has released new appropriateness criteria for cardiac computed tomography (CCT) and cardiac magnetic resonance imaging (CMR). These guidelines aim to help clinicians, patients, and payers determine when these advanced imaging tests are necessary. The criteria assess the risks and benefits of each test...
Eating a single high-fat meal can reduce the body's ability to protect itself against heart disease and stroke by impairing the 'good' cholesterol's protective qualities. In contrast, consuming polyunsaturated fat-rich meals can increase the anti-inflammatory properties of HDL, helping to prevent plaque buildup.
The revised guidelines recommend using risk factors for stroke to determine whether anti-clotting therapy is given to people with atrial fibrillation. Aspirin or warfarin is recommended for patients with certain risk factors, and daily aspirin therapy is suggested for those without stroke risk factors.
Researchers found that men with chronic coronary syndrome are more likely to experience erectile dysfunction, with an average time frame of two years between ED symptoms and angina. The study suggests that patients with ED and multiple risk factors should be monitored for heart disease.
Researchers found that pretreatment with rapamycin induces a protective effect against heart attack injury by maintaining ATP levels in heart cells. The study suggests that rapamycin may be beneficial as a potential therapeutic strategy to limit cell death and prevent long-term heart damage.
The ESC recommends developing joint clinical services with common diagnostic pathways, trained specialists in multiple imaging modalities, and evaluation of tests based on clinical outcomes. This collaboration aims to improve the quality of life of European populations by reducing cardiovascular disease's impact.
The new guidelines provide practical recommendations for evaluating patients with heart murmurs, preventing endocarditis, and treating concomitant coronary artery disease. The guidelines include more precise definitions of mild, moderate, and severe valvular disease, which may prompt earlier referrals for surgery.
The European Society of Cardiology has released updated guidelines for managing stable angina pectoris, providing recommendations on treatment methods and risk stratification. The guidelines aim to improve the quality of life for European populations affected by cardiovascular disease.
The European Society of Cardiology (ESC) has released a guidance document on Cardiac Rhythm Management product performance. The ESC proposes a novel approach for assessing individual hazard analysis to prioritize patients in need of field safety corrective actions.
The lecture highlights the evolution of interventional cardiology, from longer procedure times and higher risks of heart attacks to advancements in steerable guidewires, perfusion catheters, and drug-eluting stents. Bioabsorbable stents offer a promising solution by dissolving into carbon dioxide and water once healed.
A survey by the European Society of Cardiology found that care for adults with congenital heart disease in Europe is suboptimal, with many specialist centres failing to meet basic standards. The report identifies key areas for improvement, including the need for more trained healthcare professionals and specialized equipment.
A study found that experienced physicians can effectively auscultate the third heart sound (S3), a crucial indicator of adverse cardiovascular outcomes. The presence of S3 was associated with decreased ventricular compliance and may indicate early signs of heart failure.
The study found that TEE significantly impacted the treatment or evaluation of patients with stroke entities in 22 to 32 percent of individuals, demonstrating improved care. This research has led to increased utilization of TEE in diagnosing stroke, transient ischemic attack, and peripheral embolism.
The European Society of Cardiology recommends that patients taking Clopidogrel should continue their treatment as advised by their physicians. Stopping the anti-clotting drug without consulting a doctor may pose serious risks, according to the ESC.
Discontinuing Plavix in patients with recently-placed stents can lead to clot formation and serious complications. Patients should discuss benefits and risks of anti-clotting medication with their healthcare provider and avoid stopping the medication on their own.
A study at Temple University School of Medicine found that medical residents improved their ability to identify abnormal heart sounds by up to 69% with the use of electronic stethoscopes. Researchers used these devices to play back recorded heart sounds repeatedly, allowing residents to practice and improve their skills.
Researchers conducted a randomized trial to evaluate the effectiveness of paclitaxel-eluting stents in patients with ST-segment elevation myocardial infarction (STEMI). After one year, the study found that the drug-eluting stent reduced repeat procedures by 67% compared to bare-metal stents.
A study of 170 patients with chronic severe aortic regurgitation found that those who underwent early surgery lived longer and had better health outcomes compared to those who waited. The results support current guidelines for treatment, which recommend surgery for asymptomatic and moderately symptomatic patients.
Women's heart health is underestimated due to differing risk factors compared to men. The European Society of Cardiology recommends considering age as a significant factor in diagnosis and treatment planning for women.
A Dutch study published in European Heart Journal reveals that 43% of total heart attacks had been clinically unrecognised. Women are more likely to have atypical symptoms and may be less likely for their symptoms to be recognized by doctors.
A large-scale study has found that trained volunteers and laypeople can safely use defibrillators to save the lives of cardiac arrest victims. The study showed a significant increase in survival rates for patients in urban areas, with potential to save up to 15 out of 100 lives within an 8-minute response time.
The ESC has issued a policy statement on reperfusion therapy for STEMI treatment, highlighting the importance of early diagnosis and timely initiation of therapy. The statement recommends prioritizing primary PCI and thrombolytic treatment within three hours of symptom onset.
A new study published in the Journal of the American College of Cardiology found that hospitals using quality-improvement tactics reduced heart attack death rates by 21-26%. The effort involved a checklist to ensure patients received crucial treatments and lifestyle advice, leading to improved patient outcomes.
The new guidelines emphasize ongoing self-education and research participation, with a focus on developing physician-scientists. The report outlines specific training requirements in key areas, including echocardiography, electrophysiology, and adult congenital heart disease.
The European Society of Cardiology emphasizes the importance of healthy weight and exercise in preventing heart disease. Studies show that moderate physical activity can reduce the risk of cardiovascular events, while a balanced diet and weight management can also help mitigate the impact of existing heart conditions.
The PREAMI study found that perindopril significantly reduces the risk of death, hospitalization for heart failure, and cardiac remodelling in elderly patients after acute myocardial infarction. Perindopril reduced these outcomes by 59% and cardiac remodelling by 64%, with consistent benefits across predefined subgroups.
The IMAGINE study found that adding an ACE inhibitor within seven days of CABG surgery does not improve current optimal treatment for low-risk patients without a clear indication. The trial, led by Canadian and international researchers, aimed to investigate the benefits of early post-surgical intervention with quinapril.
A new study has shown that fondaparinux, a synthetic drug, is as effective as traditional therapy in preventing heart attacks and ischemia while reducing major bleeding risks. Patients with acute coronary syndromes who received fondaparinux had lower mortality rates at one month and six months compared to those receiving enoxaparin.
The European Society of Cardiology reports a growing problem of child obesity in Europe, with overweight and overt obesity affecting nearly all countries. Scientific evidence shows that this early onset is linked to increased risk factors such as high blood pressure, insulin resistance, and metabolic syndrome.
A European multi-centre study found that eating fish oil did little to reduce the risk of heart rhythm problems, cardiac arrest or arrhythmia in patients with an increased risk. The Study on Omega-3 Fatty acids and ventricular Arrhythmia (SOFA) investigated the effect of taking fish oil capsules on life-threatening cardiac arrhythmia i...
Acute heart failure is a significant concern, affecting approximately 30% of acute coronary syndrome patients, with female patients showing higher prevalence rates. Hospitalizations for heart failure are comparable to myocardial infarctions, with high mortality rates during hospitalization and follow-up.
The SIRIUS II clinical trial demonstrated dose-dependent favorable hemodynamic effects and improvements in cardiac output and dyspnea score in patients with acute decompensated congestive heart failure (ADHF). Ularitide was well-tolerated, preserving kidney function during treatment.
The Cardiac Insufficiency BIsoprolol Study III suggests starting patients on bisoprolol may reduce the risk of death, especially in the first year of treatment. The study found no significant differences in efficacy or tolerability between bisoprolol and ACE inhibitor initiation strategies.
The EuroAction project demonstrates a significant reduction in cardiovascular disease (CVD) risk factors through a family-based, behavioural approach. Patients and partners achieved improvements in lifestyle, cardiovascular risk factors, and medication use, including increased physical activity and healthier diets.
Researchers from Norway found that treating patients with high doses of B vitamins after a heart attack does not prevent recurrent heart disease or stroke. In fact, high doses of B vitamins may increase the risk of cardiovascular disease, particularly among those with impaired renal function.
A recent international survey found that nearly 90% of Europeans are aware of heart failure, but only 3% can identify its symptoms. The study also revealed major misconceptions about the condition, including the notion that it is a normal consequence of aging or that modern drugs cannot prevent its development.
A new study published in the American Journal of Cardiology found that early statin therapy can significantly reduce mortality and other complications in heart attack victims. Patients who received statins before or within 24 hours of hospitalization had a 54% lower risk of in-hospital mortality, compared to those not on statin therapy.
A new review of the American College of Cardiology and American Heart Association guidelines aims to streamline diagnosis and treatment of acute coronary events. The goal is to provide faster treatment that may even prevent a heart attack or damage to the heart before it happens, benefiting millions of patients each year.
Key findings highlight the importance of including women in clinical trials due to differences in response to drug therapy, such as higher levels of adverse reactions and varying mortality rates. This lack of data affects treatment strategies, with many drugs prescribed to women adapted from studies conducted mainly in men.